Journal Mobile Options
Table of Contents
Vol. 10, No. 3, 2004
Issue release date: 2004

Medical Assessment in Drug Addicts: Reliability and Validity of the Cumulative Illness Rating Scale (Substance Abuse Version)

Castillo C. · Bulbena A. · Serras E. · Torrens M. · López-Colomés J.L. · Martínez M.A. · Politinska B.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: To adapt the Cumulative Illness Rating Scale for its use in substance abuse patients (CIRS-SA) and to assess the reliability, internal consistency, and validity of the instrument. Method: One-hundred outpatients of both sexes, 62 men and 38 women, with a mean (SD) age of 32.4 (7.9) years (range 19–57), all of them fulfilling the DSM-IV criteria for any substance abuse disorder. Internal consistency was calculated with Cronbach’s α coefficient. Test-retest and interrater reliability was assessed with the intraclass correlation coefficient and Wilcoxon z. Validity of the scale was assessed with Kendall’s τ correlation coefficient. Results: The final CIRS-SA version had a total of 13 items. Cronbach’s α coefficient was 0.57. All intraclass correlation coefficients were above 0.7, and some items showed exact coincidence. The stability of the CIRS-SA scale in a 1-month test re-test reassessment was demonstrated. The CIRS-SA score showed a significant correlation with all consultant scores. Conclusion: CIRS-SA is a reliable and valid instrument to assess and to determine systematically the physical condition of substance abusers in whom infections, particularly by the HIV, are highly prevalent.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Flynn PM, Craddock SG, Hubbard RL, Anderson J, Etherigde R: Methodological overview and research design for the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav 1997;11:230–243.

    External Resources

  2. Gossop M, Marsden J, Stewart D, Lehmann P, Edwards C, Wilson A, Segar G: Substance use, health and social problems of service users at 54 drug treatment agencies. Intake data from the National Treatment Outcome Research Study. Br J Psychiatry 1998;173:166–171.
  3. Woody GE, Cottler LB, Cacciola J: Severity of dependence: Data from the DSM-IV field trials. Addiction 1993;88:1573–1579.
  4. Kanof PD, Aronson MJ, Ness R, Cochrane KJ, Horvath TB, Handelsman L: Levels of opioid physical dependence in heroin addicts. Drug Alcohol Depend 1991;27:253–262.
  5. Halikas JA, Khun KL, Crosby R, Carlson G, Crea F: The measurement of craving in cocaine patients using the Minnesota Cocaine Craving Scale. Compr Psychiatry 1991;32:22–27.
  6. Lehman AF, Myers CP, Corty E, Thompson J: Severity of substance use disorders among psychiatric inpatients. J Nerv Ment Dis 1994;182:164–167.
  7. Miele GM, Carpenter KM, Smith Cockerham M, Dietz Trauman K, Blaine J, Hasin DS: Substance Dependence Severity Scale (SDSS): Reliability and validity of a clinician-administered interview for DSM-IV substance use disorders. Drug Alcohol Depend 2000;59:63–75.
  8. Mc Lellan AT, Lubosky L, Woody GE, O’Brien CP: An improved evaluation instrument for substance abuse patients. J Nerv Ment Dis 1980;168:26–33.
  9. Darke S, Hall W, Wodak A, Heather N, Ward J: Development and validation of a multidimensional instrument for assessing outcome of treatment among opiate users: The Opiate Treatment Index. Br J Addict 1992;87:771–742.
  10. Marsden J, Gossop M, Stweart D, Best D, Farrell M, Lehmann P, Edwards C, Strang J: The Maudsley Addiction Profile (MAP): A brief instrument for assessing treatment outcome. Addiction 1998;93:1857–1868.
  11. Linn BS, Linn MW, Gurel L: Cumulative Illness Rating Scale. J Am Geriatr Soc 1968;16:622–626.
  12. Miller MD, Paradis CF, Houck PF, Mazumdar S, Stack JA, Rifai AH, Mulsant B, Reynolds CF 3rd: Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale. Psychiatr Res 1992;41:237–248.
  13. Aisen PS, Giblin KE, Parcker LS, Lawlor BA: Determinants of length of stay in geropsychiatry. Am J Geriatr Psychiatry 1994;2:165–168.
  14. Bulbena A, Jauregui JV, Zabala MJ: Indice acumulativo de enfermedad. Adaptación castellana del Cumulative Illness Rating Scale en población Psicogeriátrica. Rev Gerontol 1996, pp 313–318.
  15. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH: The use of nitrogen mustards in the palliative treatment of cancer. Cancer 1984, pp 634–656.
  16. Bartko JJ: Measurement and reliability: Statistical thinking considerations. Schizophr Bull 1991;17:483–489.
  17. Siegel S: Non-parametric Statistics for the Behavioral Sciences. New York, McGraw Hill, 1956.
  18. Bulbena A: Estudio y seguimiento de pacientes trasladados del Institut Mental de la Sta Creu i Sant Pau. Diputació de Barcelona, 1985.
  19. Parmelee PA, Thuras PD, Katz IR, Lawton MP: Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 1995;43:130–137.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50